• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Antimicrob Steward Healthc Epidemiol . On-demand, hospital-based, severe acute respiratory coronavirus virus 2 (SARS-CoV-2) genomic epidemiology to

tetano

Editor, Senior Moderator
Antimicrob Steward Healthc Epidemiol


. 2023 Mar 8;3(1):e45.
doi: 10.1017/ash.2023.119. eCollection 2023.
On-demand, hospital-based, severe acute respiratory coronavirus virus 2 (SARS-CoV-2) genomic epidemiology to support nosocomial outbreak investigations: A prospective molecular epidemiology study


Patrick Benoit[SUP] #[/SUP][SUP] 1 [/SUP], Gisèle Jolicoeur[SUP] #[/SUP][SUP] 2 [/SUP], Floriane Point[SUP] #[/SUP][SUP] 3 [/SUP], Chantal Soucy[SUP] 4 [/SUP], Karine Normand[SUP] 4 [/SUP], Philippe Morency-Potvin[SUP] 1 5 [/SUP], Simon Gagnon[SUP] 6 [/SUP], Daniel E Kaufmann[SUP] 2 3 5 [/SUP], Cécile Tremblay[SUP] 1 3 5 [/SUP], François Coutlée[SUP] 1 3 5 6 [/SUP], P Richard Harrigan[SUP] 7 [/SUP], Isabelle Hardy[SUP] 1 3 6 [/SUP], Martin Smith[SUP] 8 [/SUP], Patrice Savard[SUP] #[/SUP][SUP] 1 3 4 5 [/SUP], Simon Grandjean Lapierre[SUP] #[/SUP][SUP] 1 3 5 6 [/SUP]



Affiliations

Abstract

Objectives: We evaluated the added value of infection control-guided, on demand, and locally performed severe acute respiratory coronavirus virus 2 (SARS-CoV-2) genomic sequencing to support outbreak investigation and control in acute-care settings.
Design and setting: This 18-month prospective molecular epidemiology study was conducted at a tertiary-care hospital in Montreal, Canada. When nosocomial transmission was suspected by local infection control, viral genomic sequencing was performed locally for all putative outbreak cases. Molecular and conventional epidemiology data were correlated on a just-in-time basis to improve understanding of coronavirus disease 2019 (COVID-19) transmission and reinforce or adapt control measures.
Results: Between April 2020 and October 2021, 6 outbreaks including 59 nosocomial infections (per the epidemiological definition) were investigated. Genomic data supported 7 distinct transmission clusters involving 6 patients and 26 healthcare workers. We identified multiple distinct modes of transmission, which led to reinforcement and adaptation of infection control measures. Molecular epidemiology data also refuted (n = 14) suspected transmission events in favor of community acquired but institutionally clustered cases.
Conclusion: SARS-CoV-2 genomic sequencing can refute or strengthen transmission hypotheses from conventional nosocomial epidemiological investigations, and guide implementation of setting-specific control strategies. Our study represents a template for prospective, on site, outbreak-focused SARS-CoV-2 sequencing. This approach may become increasingly relevant in a COVID-19 endemic state where systematic sequencing within centralized surveillance programs is not available.
Trial registration: clinicaltrials.gov identifier: NCT05411562.
 
Back
Top Bottom